{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:58:58Z","timestamp":1781053138146,"version":"3.54.1"},"reference-count":11,"publisher":"BMJ","issue":"2","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Pract Neurol"],"accepted":{"date-parts":[[2019,8,27]]},"published-print":{"date-parts":[[2020,4]]},"abstract":"<jats:p>Cytotoxic agents such as cyclophosphamide are infrequently used in neurological practice. When they are, it is commonly in critically ill patients or in those with refractory inflammatory disorders. Cyclophosphamide in particular has a well-recognised negative impact on both female and male long-term fertility. This article summarises the data with regards the impact of cytotoxics on long-term fertility and describes the current options to preserve fertility in these patients. We hope this will provide neurologists with a useful aid for counselling patients for whom they are considering these treatments.<\/jats:p>","DOI":"10.1136\/practneurol-2019-002247","type":"journal-article","created":{"date-parts":[[2019,9,13]],"date-time":"2019-09-13T17:24:24Z","timestamp":1568395464000},"page":"148-153","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":11,"title":["Preserving fertility: using cyclophosphamide and other cytotoxics in young people"],"prefix":"10.1136","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6474-2666","authenticated-orcid":false,"given":"David","family":"Ledingham","sequence":"first","affiliation":[{"name":"Neurology, James Cook University Hospital, Middlesbrough, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Plant","sequence":"additional","affiliation":[{"name":"Rheumatology, James Cook University Hospital, Middlesbrough, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fayez","family":"Mustafa","sequence":"additional","affiliation":[{"name":"Reproductive Medicine, James Cook University Hospital, Middlesbrough, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhimanagouda","family":"Patil","sequence":"additional","affiliation":[{"name":"Neurology, James Cook University Hospital, Middlesbrough, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,9,13]]},"reference":[{"key":"2025090410300951000_20.2.148.1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197704)39:4<1403::AID-CNCR2820390408>3.0.CO;2-8"},{"key":"2025090410300951000_20.2.148.2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1988.03720140043031"},{"key":"2025090410300951000_20.2.148.3","unstructured":"Human Fertilisation and Embryology Authority . Egg freezing in fertility treatment 2010-2016, 2017. Available: www.hfea.go.uk\/media\/2656\/egg-freezing-in-fertility-treatment-trends-and-figures-2010-2016-final.pdf"},{"key":"2025090410300951000_20.2.148.4","unstructured":"Human Fertilisation and Embryology Authority . Fertility treatment 2017: trends and figures, 2019. Available: www.hfea.gov.uk\/media\/2894\/fertility-treatment-2017-trends-and-figures-may-2019.pdf"},{"key":"2025090410300951000_20.2.148.5","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1200\/JCO.2018.78.0858","article-title":"Gonadotropin-Releasing hormone agonists during chemotherapy for preservation of ovarian function and fertility in premenopausal patients with early breast cancer: a systematic review and meta-analysis of individual patient-level data","volume":"36","author":"Lambertini","year":"2018","journal-title":"J Clin Oncol"},{"key":"2025090410300951000_20.2.148.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1614676"},{"key":"2025090410300951000_20.2.148.7","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/S0140-6736(15)60198-2","article-title":"Fertility preservation for age-related fertility decline","volume":"385","author":"Donnez","year":"2015","journal-title":"Lancet"},{"key":"2025090410300951000_20.2.148.8","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1002\/rmb2.12268","article-title":"Current state and future possibilities of ovarian tissue transplantation","volume":"18","author":"Takae","year":"2019","journal-title":"Reprod Med Biol"},{"key":"2025090410300951000_20.2.148.9","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/dev190"},{"key":"2025090410300951000_20.2.148.10","unstructured":"National Institute of Health and Care Excellence . Fertility problems: assessment and treatment (NICE guideline 156), 2017. Available: https:\/\/www.nice.org.uk\/guidance\/cg156"},{"key":"2025090410300951000_20.2.148.11","doi-asserted-by":"crossref","DOI":"10.1186\/s13023-015-0332-8","article-title":"Immunosuppressive drugs and fertility","volume":"10","author":"Leroy","year":"2015","journal-title":"Orphanet J Rare Dis"}],"container-title":["Practical Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/practneurol-2019-002247","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T17:30:25Z","timestamp":1757007025000},"score":1,"resource":{"primary":{"URL":"https:\/\/pn.bmj.com\/lookup\/doi\/10.1136\/practneurol-2019-002247"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,13]]},"references-count":11,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,3,17]]},"published-print":{"date-parts":[[2020,4]]}},"alternative-id":["10.1136\/practneurol-2019-002247"],"URL":"https:\/\/doi.org\/10.1136\/practneurol-2019-002247","relation":{},"ISSN":["1474-7758","1474-7766"],"issn-type":[{"value":"1474-7758","type":"print"},{"value":"1474-7766","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,13]]}}}